Background {#s1}
==========

The natural history of a mycotic abdominal aortic aneurysm (MAAA) is that of a rapid progression to rupture and usually death.[@R1] [@R2] *Campylobacter fetus* is an actual infective agent for MAAA, especially in elderly or debilitated patients.[@R3] [@R4] We report here the first case efficiently treated by endovascular aortic repair (EVAR) and antibiotic therapy. In frail patients, EVAR could be a suitable alternative, allowing immediate less invasive treatment. Even if it is generally considered a bridge therapy, it could also sometimes represent a more durable treatment option with total remission of the infection.

Case presentation {#s2}
=================

A 73-year-old male patient presented to our emergency department after 4 days of fever, chills and pain in the lower abdomen irradiating to the back. He also reported having diarrhoea for 3 days. Medical history was relevant for ischaemic and hypertensive heart disease. Seven days previously he had a coronarography. He had a temperature of 37.8°C, normal blood pressure and heart rate and abdominal pain without signs of peritonitis. No pulsatile abdominal mass was palpable.

Investigations {#s3}
==============

Blood tests showed an elevated white cell count of 15.5 G/L (normal value: 4--10 G/L), an elevated C reactive protein of 315 mg/L (normal value\<5 mg/L) and a haemoglobin value of 105 g/L (normal value: 120--180 g/L). An abdominal CT scan showed a partially thrombosed infrarenal atherosclerotic aortic aneurysm of 38 mm with periaortitis ([figure 1](#BCR2016215582F1){ref-type="fig"}). A CT scan performed the next day because of worsening abdominal pain showed a contained rupture ([figure 2](#BCR2016215582F2){ref-type="fig"}A, B). Blood cultures were positive for *C. fetus*.

![Abdominal CT scan showing an infrarenal atheroscleroting aortic aneurysm of 38 mm with periaortitis.](bcr2016215582f01){#BCR2016215582F1}

![(A and B) CT scan performed the second day because of acute abdominal pain showing signs of contained rupture.](bcr2016215582f02){#BCR2016215582F2}

Differential diagnosis {#s4}
======================

Contained rupture of a MAAA following infectious aortitis was the main diagnostic hypothesis. The hypothesis of a postcoronarography aneurysmal infection was invalidated by the blood cultures showing *C. fetus*, no cutaneous germs and by the absence of previous aneurysmal disease.

Treatment {#s5}
=========

Intravenous empiric antibiotic treatment with amoxicilline--clavulanate was initiated immediately after the first abdominal CT scan, and the patient was admitted to the intensive care unit. He was operated 24 hours later after clinical deterioration and a CT scan showing a contained rupture of the aneurism. He was considered unfit for open surgery because of severe ischaemic heart disease. A 'bridge therapy' with EVAR was therefore planned. He underwent a percutaneous endovascular aneurysmal exclusion with endograft (Endurant II ETLW 16×16 C 93 and ETLW 16×16 C 82) under local anaesthesia. After blood cultures were found to be positive for *C. fetus*, the initial antibiotic therapy was replaced by an intravenous treatment with imipenem--cilastatin for 3 weeks followed by oral ciprofloxacin for 3 weeks.

Outcome and follow-up {#s6}
=====================

Our patient had a favourable postoperative outcome. An abdominal CT scan on postoperative day 3 showed exclusion of the aneurysm by the endoprosthesis. A small type II endoleak required no specific treatment. The patient was discharged 9 days after surgery and followed up regularly. At 12 months, the clinical evolution was favourable. The clinical examination and CT scan showed no endoleak or signs of infection, so it was decided not to convert to open surgery.

Discussion {#s7}
==========

The entity of mycotic aneurysm was first described by William Osler in 1885.[@R2] The term is, however, misleading since the majority of mycotic aneurysms are due to bacterial infection and are not fungal in nature. Since the classical triad of fever, abdominal pain and pulsatile abdominal mass is not always present, the diagnosis of a mycotic aneurysm can be very challenging and requires a high degree of suspicion.[@R3] [@R4] The most commonly cultured organisms include *Staphylococcus* (30%), *Streptococcus* (10%) and *Salmonella* (10%).[@R1] Other microorganisms such as *Brucella* can be responsible for aortitis.[@R5] *C. fetus* is a very rare cause of mycotic aneurysm especially in the elderly with other underlying pathologies.[@R3] In our case, the patient was an elderly ex-smoker with ischaemic heart disease and a recent history of gastroenteritis. He was not known for having an abdominal aortic aneurysm. During hospitalisation, he had no gastrointestinal symptoms and stool cultures that could have shown that he was an asymptomatic germ carrier were unfortunately not performed. The fact that the blood cultures were positive for *C. fetus* indicates that the patient had in all probability first suffered from bacteraemia with *C. fetus*, which led to an aortits that itself degenerated into a mycotic aneurysm. Regarding the treatment of MAAA, antibiotic therapy is essential but is inadequate if given alone.[@R3] [@R6] The appropriate dose, duration and regimen of antibiotic therapy have not yet been established. Some authors report that a period of 4--8 weeks of antibiotic treatment is sufficient, whereas others insist on lifelong antibiotic therapy.[@R1] [@R3] There is no widely accepted consensus on this point, and the indications must therefore be determined case by case. Surgical intervention for MAAA remains challenging. Extra-anatomic bypass has been replaced[@R9] by in situ graft replacement surgery as the gold standard treatment.[@R4] [@R10] EVAR has been introduced as an alternative allowing minimally invasive intervention with prompt aneurysmal exclusion and immediate control of bleeding. It is particularly useful in the case of severely ill or elderly patients. Until recently, EVAR was considered to be a temporary treatment prior to definitive open repair and was therefore called a 'bridge to open surgery'.[@R2] However, a recent study comparing the results of EVAR with those of conventional surgery for treatment of MAAA showed that EVAR appears to be equivalent to surgery.[@R4] Additionally, the European multicentre collaboration trial, the largest ever on mycotic aortic aneurysm, studied the durability of EVAR by assessing late infection-related complications and long-term survival. The study concludes that EVAR can be a durable treatment option for most patients. Open repair shows short-term mortality rates of 20--40% and significant short-term and long-term morbidities related to the operation with a 5-year survival of 35%.[@R2] According to the same study, EVAR has a good short-term outcome with 91% survival at 30 days and 55% at 5 years. However, the implantation of prosthetic material in an infected site remains a major problem. The study shows 19% of fatal infection-related complications, mostly occurring during the first postoperative year for EVAR, versus only 7--10% for open surgery. Non-Salmonella-positive blood cultures seem to be the main factor associated with serious late infectious complications.[@R2] Long-term antibiotic treatment and strict follow-up are required in order to minimise late infections that are often fatal. Our patient was successfully treated with EVAR and 6 weeks of antibiotics. At 1 year, he showed no signs of infectious complications. To the best of our knowledge, this is the 29th case of MAAA infected with *C. fetus* to be reported in the English literature and the first case to be successfully treated with EVAR ([table 1](#BCR2016215582TB1){ref-type="table"}).[@R1] [@R6]

###### 

A summary of mycotic abdominal aneurysms caused by *Campylobacter fetus*

  Author                      Year   Antibiotic therapy   Operation                        Outcome
  --------------------------- ------ -------------------- -------------------------------- --------------------------------
  Dolev *et al*[@R6]          1971   --                   Replaced-Dacron graft            Died few hours after operation
  File *et al*[@R7]           1979   --                   --                               Died before operation
  Taylor *et al*[@R8]         1979   --                   --                               Died before operation
  Anolik *et al*[@R9]         1983   Long term            Aneurysm excision, AXBF          Alive, 45 months
  Marty *et al*[@R10]         1983   7 months             Replaced-Dacron graft            Alive, 2 years
  Blabey *et al*[@R11]        1983   7 weeks              Aneurysm excision, AXBF          Alive, 18 months
  Righter Woods[@R12]         1985   1 week               Replaced-Dacron graft            Alive, 3 years
  Perry[@R13]                 1985   8 weeks              Replaced-Dacron graft            Alive, 6 months
  Rutherford *et al*[@R14]    1989   5 months             Dacron graft                     Alive, 2 years
  Jacobs *et al*[@R15]        1989   --                   Aneurysm excision, AXBF          Died after 7 days
  Kato *et al*[@R16]          1990   2 weeks              Aneurysm excision, AXBF          Alive, 36 months
  Allerberger *et al*[@R17]   1991   --                   --                               Died, before operation
  Grollier *et al*[@R18]      1993   --                   Replaced-Dacron graft            ND
  Mii *et al*[@R19]           1998   3 months             Replaced-Dacron graft            Alive, 1 year
  Tran *et al*[@R20]          2007   Life long            Replaced-Polyester graft         Alive, 9 months
  Cochennec *et al*[@R21]     2008   Long term            Replaced-Dacron graft            Alive, 6 months
  Cochennec *et al*[@R21]     2008   Long term            Dacron graft                     Alive, 5 months
  Cochennec *et al*[@R21]     2008   Long term            EVAR                             Died, after 2 weeks
  Cochennec *et al*[@R21]     2008   Long term            Replaced-Allograft               Alive, 18 months
  Brossier *et al*[@R22]      2010   --                   Replaced-Dacron graft            Alive, 34 months
  Brossier *et al*[@R22]      2010   --                   Replaced- Silver graft           Alive, 28 months
  Brossier *et al*[@R22]             --                   Replaced-Dacron graft            Alive, 5 months
  Brossier *et al*[@R22]      2010   --                   EVAR                             Died, after 15 days
  Brossier *et al*[@R22]      2010   --                   Replaced-Allograft               Alive, 38 months
  Maeda *et al*[@R1]          2011   --                   Replaced-Polyester graft         Alive
  Maeda *et al*[@R1]          2011   --                   Replaced-Polyester graft         Alive
  Noda *et al*[@R23]          2011   More than 4 weeks    Replaced-Dacron graft            Alive, 1 year
  Hagiya *et al*[@R24]        2013   Long term            Replaced-Polyester J graft       Alive, 1 year
  Present case                2015   6 weeks              EVAR (Endurant II stent graft)   Alive, 1 year

AXBF, axillobifemoral bypass operation; EVAR, endovascular aortic repair.

###### Learning points

-   Mycotic aneurysms are rare, regardless of aetiology, and should be suspected when symptoms and patient characteristics make it an actual differential diagnosis. In such circumstances, a CT scan and blood cultures are mandatory.

-   Ideal duration of antibiotic treatment has not yet been established. In our case, 6 weeks seem to have been sufficient; however, follow-up is probably too short for final conclusions.

-   This case supports the use of EVAR in patients with mycotic aneurysms with *Campylobacter fetus*, even though earlier attempts of EVAR in similar cases failed.
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